Characteristics of the 87 Patients
| Characteristic | Data |
| Age (y) | |
| Mean | 46.1 |
| Range | 26–73 |
| ≤50 | 60 (69.0%) |
| 50 | 27 (31.0%) |
| RCB index | |
| RCB-0 | 17 (19.5%) |
| RCB-1 | 6 (6.9%) |
| RCB-2 | 42 (48.3%) |
| RCB-3 | 22 (25.3%) |
| Clinical T stage | |
| I | 12 (13.8%) |
| II | 61 (70.1%) |
| III | 9 (10.3%) |
| IV | 5 (5.7%) |
| Clinical N stage | |
| I | 53 (60.9%) |
| II | 12 (13.8%) |
| III | 22 (25.3%) |
| Modifier Bloom–Richardson score | |
| I | 10 (11.5%) |
| II | 29 (33.3%) |
| III | 19 (21.8%) |
| Estrogen receptor | |
| Positive | 36 (41.4%) |
| Negative | 51 (58.6%) |
| Progesterone receptor | |
| Positive | 29 (33.3%) |
| Negative | 58 (67.7%) |
| HER2 | |
| Positive | 42 (48.3%) |
| Negative | 45 (51.7%) |
| Ki-67 | |
| High | 30 (34.5%) |
| Low | 56 (64.4%) |
| Subtype | |
| Luminal A | 22 (25.3%) |
| Luminal B | 17 (19.5%) |
| HER2 | 27 (31.0%) |
| Triple-negative | 21 (24.1%) |
| pCR-positive | 17 (19.5%) |
Except for age, data are number of patients.